Download PDF
Am J Perinatol 2024; 41(S 01): e2410-e2417
DOI: 10.1055/s-0043-1771260
Original Article

Efficacy and Safety of Aspirin 162 mg for Preeclampsia Prophylaxis in High-Risk Patients

Mariam Ayyash 
1   Department of Obstetrics and Gynecology, Henry Ford Health, Detroit, Michigan
,
Gregory Goyert
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Henry Ford Health, Detroit, Michigan
,
Robyn Garcia
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Henry Ford Health, Detroit, Michigan
,
Raminder Khangura
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Henry Ford Health, Detroit, Michigan
,
D'Angela Pitts
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Henry Ford Health, Detroit, Michigan
,
Gordon Jacobsen
3   Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan
,
Majid Shaman
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Henry Ford Health, Detroit, Michigan
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective The aim of this study was to compare the safety and efficacy of aspirin 162 mg to the standard recommended dose of 81 mg for preeclampsia prevention.

Study Design A retrospective cohort study of patients at risk for preeclampsia who delivered between January 2013 and December 2020 at Henry Ford Health was performed. Patients were divided into three groups: a no aspirin group, a group treated under an 81 mg aspirin preeclampsia prophylaxis protocol, and a group treated under a 162 mg protocol. Univariate and multivariable logistic regression analyses compared rates of preeclampsia and secondary outcomes between groups. Clinical side effects traditionally associated with aspirin use were also assessed.

Results Of 3,597 patients, 2,266 (63%) were in the no aspirin group, 944 (26%) were in the 81 mg group, and 387 (11%) were in the 162 mg group. The rate of preeclampsia was significantly lower in the 162 mg group (10.1%, odds ratio, 0.68; 95% confidence interval, 0.46–0.99) compared with the 81 mg group (14.2%). The rate of preeclampsia was identical in the no aspirin and 81 mg groups. The rate for postpartum hemorrhage, postpartum hematoma, and intraventricular hemorrhage of the newborn were not significantly different between patients in the 162 and 81 mg groups.

Conclusion We observed a significantly lower rate of preeclampsia in high-risk patients who were treated with the 162 mg dose of aspirin for preeclampsia prophylaxis, and bleeding complications were not seen with the higher dose. Our study suggests that aspirin 162 mg may be considered for prophylaxis in patients at high risk for preeclampsia.

Key Points

  • Aspirin 81 mg is currently standard for preeclampsia prophylaxis.

  • Preeclampsia rate is significantly lower among high-risk patients taking aspirin 162 mg compared with 81 mg.

  • Bleeding complications are not increased among those taking aspirin 162 mg.

Keywords

preeclampsia - aspirin - prophylaxis - high-risk pregnancies

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.




Publication History

Received: 19 March 2023

Accepted: 15 June 2023

Article published online:
29 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020; 135 (06) e237-e260
    CrossrefPubMedSearch in Google Scholar
  • 2 Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376 (9741): 631-644
    CrossrefPubMedSearch in Google Scholar
  • 3 Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003; 22 (02) 203-212
    CrossrefPubMedSearch in Google Scholar
  • 4 Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160 (10) 695-703
    CrossrefPubMedSearch in Google Scholar
  • 5 Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179 (05) 1359-1375
    CrossrefPubMedSearch in Google Scholar
  • 6 Crocker IP, Cooper S, Ong SC, Baker PN. Differences in apoptotic susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Am J Pathol 2003; 162 (02) 637-643
    CrossrefPubMedSearch in Google Scholar
  • 7 Leung DN, Smith SC, To KF, Sahota DS, Baker PN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001; 184 (06) 1249-1250
    CrossrefPubMedSearch in Google Scholar
  • 8 Levine RJ, Lam C, Qian C. et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. [published erratum appears in N Engl J Med 2006;355: 1840] N Engl J Med 2006; 355 (10) 992-1005
    CrossrefPubMedSearch in Google Scholar
  • 9 Espinoza J. Uteroplacental ischemia in early- and late-onset pre-eclampsia: a role for the fetus?. Ultrasound Obstet Gynecol 2012; 40 (04) 373-382
    CrossrefPubMedSearch in Google Scholar
  • 10 Benigni A, Gregorini G, Frusca T. et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989; 321 (06) 357-362
    CrossrefPubMedSearch in Google Scholar
  • 11 Schiff E, Peleg E, Goldenberg M. et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989; 321 (06) 351-356
    CrossrefPubMedSearch in Google Scholar
  • 12 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369 (9575): 1791-1798
    CrossrefPubMedSearch in Google Scholar
  • 13 LeFevre ML. U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161 (11) 819-826
    CrossrefPubMedSearch in Google Scholar
  • 14 Low-dose aspirin use during pregnancy. ACOG Committee Opinion No. 743. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018; 132: e44-e52
    CrossrefPubMedSearch in Google Scholar
  • 15 CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343 (8898): 619-629
    CrossrefPubMedSearch in Google Scholar
  • 16 Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. Br J Obstet Gynaecol 1995; 102 (11) 861-868
    CrossrefPubMedSearch in Google Scholar
  • 17 Bujold E, Roberge S, Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 pt. 1): 402-414
    CrossrefPubMedSearch in Google Scholar
  • 18 Roberge S, Villa P, Nicolaides K. et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012; 31 (03) 141-146
    CrossrefPubMedSearch in Google Scholar
  • 19 Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 110-120.e6
    CrossrefPubMedSearch in Google Scholar
  • 20 Lowe SA, Bowyer L, Lust K. et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol 2015; 55 (05) e1-e29
    CrossrefPubMedSearch in Google Scholar
  • 21 O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open 2016; 6 (06) e011801
    CrossrefPubMedSearch in Google Scholar
  • 22 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
    CrossrefPubMedSearch in Google Scholar
  • 23 Poon LC, Wright D, Rolnik DL. et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol 2017; 217 (05) 585.e1-585.e5
    CrossrefPubMedSearch in Google Scholar
  • 24 Wright D, Rolnik DL, Syngelaki A. et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol 2018; 218 (06) 612.e1-612.e6
    CrossrefPubMedSearch in Google Scholar
  • 25 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2 (02) CD004659
    PubMedSearch in Google Scholar
  • 26 Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994; 171 (04) 892-900
    CrossrefPubMedSearch in Google Scholar
  • 27 Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus–related to maternal pain medication?. Z Geburtshilfe Neonatol 2005; 209 (02) 65-68
    Thieme ConnectPubMedSearch in Google Scholar
  • 28 Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79 (06) 1165-1177
    CrossrefPubMedSearch in Google Scholar
  • 29 Bujold E, Roberge S, Lacasse Y. et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1): 402-414
    CrossrefPubMedSearch in Google Scholar
  • 30 Hastie R, Tong S, Wikström AK, Sandström A, Hesselman S, Bergman L. Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. Am J Obstet Gynecol 2021; 224 (01) 95.e1-95.e12
    CrossrefPubMedSearch in Google Scholar